Tickers

1. Composite Trajectory Verdict

Given CSW's acquisitive industrial growth model, the income statement and cash flow statement carry the most weight for assessing operational performance, while the balance sheet reflects financing choices for acquisitions.

Composite Trajectory: Mixed

Revenue growth remains strong at +23.3% YoY in FY2026 (10-K FY2026, Consolidated Statements of Operations), driven primarily by acquisitions. However, operating income declined 7.0% and net income fell 17.9% in FY2026 as margins compressed from acquisition integration costs, intangible amortization, and a $15.6M Greco impairment. Operating cash flow has declined for two consecutive years. The Q1 FY2027 quarter shows margin improvement (operating margin 22.8% vs 20.8% YoY), but only one quarter of post-acquisition data is available. The balance sheet has leveraged significantly with debt rising from zero to $871.5M gross.

2. Red Flags

• Operating income decreased 7.0% YoY in FY2026 to $168.5M despite 23.3% revenue growth (10-K FY2026, Consolidated Statements of Operations)
• Operating margin compressed from 20.6% (FY2025) to 15.6% (FY2026) (10-K FY2026, Consolidated Statements of Operations)
• Net income fell 17.9% YoY in FY2026 to $112.8M (10-K FY2026, Consolidated Statements of Operations)
• Operating cash flow declined for two consecutive years: $149.7M (FY2026) vs $168.4M (FY2025) vs $164.3M (FY2024) (10-K FY2026, Consolidated Statements of Cash Flows)
• Total debt increased from $0 to $871.5M gross ($839.8M net long-term) in FY2026 (10-K FY2026, Note 9)
• Cash balance dropped from $225.8M to $33.8M in FY2026 (10-K FY2026, Consolidated Statements of Cash Flows)
• Goodwill impairment of $7.5M and total Greco business impairment of $15.6M recorded in FY2026 (10-K FY2026, Note 4 and Note 7)
• Contingent consideration liabilities of $16.7M at March 31, 2026 (10-K FY2026, Note 14)
• Share repurchases of $127.5M in FY2026 funded partly by new debt (10-K FY2026, Consolidated Statements of Cash Flows)
• Working capital consumed cash in both FY2026 ($36.8M inventory, $27.1M receivables) and FY2025 (10-K FY2026, MD&A Liquidity)

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual revenue grew 23.3% to $1.08B in FY2026 (10-K FY2026, Consolidated Statements of Operations), with acquisitions contributing $222.6M and organic sales declining 2.1%. Gross profit rose 15.3% to $453.7M but margin fell to 41.9% from 44.8% due to acquisition mix, tariffs, and integration costs. Operating income declined 7.0% to $168.5M (15.6% margin) as SG&A surged 34.5% to $285.1M from acquisition amortization, $15.6M Greco impairment, and integration expenses. Net income fell 17.9% to $112.8M. Quarterly Q1 FY2027 showed improvement: revenue +33.0% to $350.7M, gross margin 44.9% vs 43.8%, operating margin 22.8% vs 20.8% (10-Q Q1 FY2027, MD&A), but this reflects only one quarter with full acquisition inclusion.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash flow has declined two consecutive years to $149.7M in FY2026 from $168.4M in FY2025 and $164.3M in FY2024 (10-K FY2026, Consolidated Statements of Cash Flows). Working capital was a consistent cash drain: inventories consumed $36.8M and receivables $27.1M in FY2026; inventories $35.7M and receivables $9.1M in FY2025 (10-K FY2026, MD&A Liquidity). Investing cash flow swung to -$1.04B in FY2026 from -$102.2M in FY2025 due to $1.02B of acquisition spending (10-K FY2026, Consolidated Statements of Cash Flows). Financing inflows of $701.5M (primarily $600M TLA and $505.7M revolver draws) funded acquisitions and $127.5M share repurchases. Quarterly cash flow statements for Q1 FY2027 are not provided in the 10-Q.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

Total assets nearly doubled to $2.32B from $1.38B in FY2025, driven by $368.5M goodwill increase (to $632.6M) and $542.1M intangible asset increase (to $900.1M) from acquisitions (10-K FY2026, Consolidated Balance Sheets). Total debt went from zero to $871.5M gross ($279M revolver + $592.5M TLA) with $839.8M classified as long-term (10-K FY2026, Note 9). Equity declined slightly to $1.05B from $1.07B despite $112M net income, as $127.5M share repurchases and $18M dividends exceeded retained earnings growth (10-K FY2026, Consolidated Statements of Equity). Redeemable noncontrolling interest fell to $19.0M from $20.2M after $2.0M distribution (10-K FY2026, Note 3). Leverage increased substantially; covenant compliance was maintained at March 31, 2026 (10-K FY2026, Note 9).

6. Data Gaps

• FY2024 full balance sheet (total assets, total liabilities) not fully extractable from provided 10-K XBRL
• Quarterly cash flow statements for Q1 FY2027 and Q1 FY2026 not included in 10-Q filing
• Quarterly balance sheets not provided in 10-Q
• Segment-level quarterly revenue and operating income for Q1 FY2027 vs Q1 FY2026
• Organic revenue growth by segment for full FY2026 (only consolidated organic -2.1% disclosed)
• FY2027 quantitative guidance beyond qualitative outlook statements
• Free cash flow trajectory (capex relatively stable at ~$17M annually but acquisition spending dominates investing)